CCL5 hi Macrophages Interact with CD8 + T Cells and Potentiate Responsiveness to PD‐1 Blockade Plus Chemotherapy in Esophageal Squamous Cell Carcinoma
Advanced Science · 2025
DOI: 10.1002/advs.202409187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yuanzhen Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, CD8-Positive T-Lymphocytes, Chemokine CCL5. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Esophageal Cancer Institute Project, Guangdong Basic & Applied Basic Research-Hybribio Joint Fund.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Immunotherapy has significantly transformed cancer therapy and reinvigorated research in cancer immunology. Several clinical trials have employed neoadjuvant immunochemotherapy (NIC) for advanced esophageal squamous cell carcinoma (ESCC), resulting in significant benefits for many patients. However, response rates remain limited, underscoring the need for more effective screening methods and novel therapeutic strategies. Tumor‐associated macrophages (TAMs) have been shown to play a crucial role in tumor progression and impact the clinical outcomes of cancer patients. Nonetheless, it is worth noting that TAMs exhibit phenotypic and functional heterogeneity. In this study, a distinct population of CCL5 hi macrophages is identified that plays a critical role in ESCC when treated with immunochemotherapy. Furthermore, insights are gained into the underlying mechanisms, revealing the existence of a feedback loop involving IFN‐γ, CCL5 hi macrophages, and CD8 + T cells within the tumor microenvironment of ESCC undergoing immunochemotherapy. Specific signatures associated with CCL5 hi macrophages are correlated with a better response to immunochemotherapy in patients with ESCC. Moreover, the in vivo experiments demonstrate that CCL5 supplementation enhances the effectiveness of immunochemotherapy. This research contributes to the optimization of patient stratification and provides a rationale for novel combinatorial approaches involving immunotherapy in the treatment of ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
- Guangdong Esophageal Cancer Institute, Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
- Department of Clinical Oncology, The University of Hong kong, Hong Kong, China.
ORCID-Profile: Yan Li
Förderung
- National Natural Science Foundation of China
- Guangdong Esophageal Cancer Institute Project
- Guangdong Basic & Applied Basic Research-Hybribio Joint Fund
Zitieren
APA
Ma, Y., Su, X., Zeng, T., Zhou, C., Yang, G., Xia, Z., Zeng, C., Zhan, J., Guan, X. Y., Zhang, X., & Li, Y. (2025). CCL5 hi Macrophages Interact with CD8 + T Cells and Potentiate Responsiveness to PD‐1 Blockade Plus Chemotherapy in Esophageal Squamous Cell Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202409187
Vancouver
Ma Y, Su X, Zeng T, Zhou C, Yang G, Xia Z, et al. CCL5 hi Macrophages Interact with CD8 + T Cells and Potentiate Responsiveness to PD‐1 Blockade Plus Chemotherapy in Esophageal Squamous Cell Carcinoma. Advanced Science. 2025. doi:10.1002/advs.202409187
BibTeX
@article{Ma2025,
author = {Ma, Yuanzhen and Su, Xiaodong and Zeng, Tingting and Zhou, Chunlian and Yang, Guozhen and Xia, Zengfei and Zeng, Chufeng and Zhan, Jiarong and Guan, Xin-Yuan and Zhang, Xu and Li, Yan},
title = {CCL5 hi Macrophages Interact with CD8 + T Cells and Potentiate Responsiveness to PD‐1 Blockade Plus Chemotherapy in Esophageal Squamous Cell Carcinoma},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202409187}
}
EUVIMED